Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Freenome, Inc.FRNM · Entity 4644 | Director | July 20, 2026 | July 28, 2026 |
| NEOGENOMICS INCNEO · Entity 2096 | Director | August 01, 2021 | August 13, 2021 |
| RENOVARE ENVIRONMENTAL, INC.BHTG · Entity 128802 | Director | May 24, 2018 | May 25, 2018 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Freenome, Inc.
Report date July 20, 2026 · Filed July 28, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 20,867 |
Reported balance
Holding disclosure · report date 2026-07-20 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 20,867 |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $14.00 · Expires 2035-05-28 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2026-07-20 · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · Balance Not disclosed F3: This option was previously amended, pursuant to which the exercise price of the option will be automatically reduced to $8.45 upon the occurrence of certain events. F1: The shares subject to this option are fully vested. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $14.00 · Expires 2035-05-28 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2026-07-20 · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · Balance Not disclosed F3: This option was previously amended, pursuant to which the exercise price of the option will be automatically reduced to $8.45 upon the occurrence of certain events. F2: 25% of the shares subject to this option shall vest and become exercisable on June 3, 2025 with the remainder vesting in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.45 · Expires 2035-10-23 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2026-07-20 · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · Balance Not disclosed F1: The shares subject to this option are fully vested. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares subject to this option are fully vested.
F2: 25% of the shares subject to this option shall vest and become exercisable on June 3, 2025 with the remainder vesting in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date.
F3: This option was previously amended, pursuant to which the exercise price of the option will be automatically reduced to $8.45 upon the occurrence of certain events.
NEOGENOMICS INC
Report date August 01, 2021 · Filed August 13, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 2,468,797 |
Reported balance
After 2021-08-01 transaction · row 2
1 source rowRow 2 · 2021-08-01 · Tax withholding · Disposed 5,919 · Balance 2,468,797 F1: Shares surrendered to NeoGenomics Inc. to satisfy the tax obligations in connection with the August 1, 2021 vesting of restricted stock. |
| Common StockSEC Table I · non-derivative | IndirectCustodial Account for Child | 15,000 |
Reported balance
Holding disclosure · report date 2021-08-01 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 15,000 |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.03 · Expires 2023-02-26 | Direct | 500,000 |
Reported balance
Holding disclosure · report date 2021-08-01 · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · Balance 500,000 F2: On February 26, 2018, Mr. VanOort was granted 500,000 stock options. These options vested ratably over the first three anniversary dates of the grant date. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $19.60 · Expires 2024-03-01 | Direct | 231,567 |
Reported balance
Holding disclosure · report date 2021-08-01 · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · Balance 231,567 F3: On March 1, 2019, Mr. VanOort was granted 231,567 stock options. These options vest ratably over the first four anniversary dates of the grant date. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $28.33 · Expires 2027-03-02 | Direct | 225,084 |
Reported balance
Holding disclosure · report date 2021-08-01 · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · Balance 225,084 F4: On March 2, 2020, Mr. VanOort was granted 225,084 stock options. These options vest ratably over the first four anniversary dates of the grant date. |
Filing footnotes · ownership attribution and instrument terms
F1: Shares surrendered to NeoGenomics Inc. to satisfy the tax obligations in connection with the August 1, 2021 vesting of restricted stock.
F2: On February 26, 2018, Mr. VanOort was granted 500,000 stock options. These options vested ratably over the first three anniversary dates of the grant date.
F3: On March 1, 2019, Mr. VanOort was granted 231,567 stock options. These options vest ratably over the first four anniversary dates of the grant date.
F4: On March 2, 2020, Mr. VanOort was granted 225,084 stock options. These options vest ratably over the first four anniversary dates of the grant date.
RENOVARE ENVIRONMENTAL, INC.
Report date May 24, 2018 · Filed May 25, 2018
Jointly reported with CONUNDRUM CAPITAL PARTNERS, LLC
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, par value $0.0001SEC Table I · non-derivative | IndirectHeld by Conundrum Capital Partners, LLC | 914,427 |
Last balance in matching sequence
After 2018-05-24 transaction · row 2
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
2 source rowsRow 1 · 2018-05-24 · Conversion · Acquired 36,364 · Balance 913,228 F2: 36,364 shares at $2.75 per share represent the conversion at maturity of a convertible note initially entered into on August 17, 2017. F1: Douglas M. VanOort holds voting and dispositive control over Conundrum Capital Partners, LLC. Row 2 · 2018-05-24 · Conversion · Acquired 1,199 · Balance 914,427 F3: 1,199 shares at $4.30 per share represent the payment of interest at 8% on the note. F1: Douglas M. VanOort holds voting and dispositive control over Conundrum Capital Partners, LLC. |
| Convertible Promissory NoteSEC Table II · derivative / convertible security · Conversion / exercise price $2.75 · Expires 2018-05-24 | IndirectHeld by Conundrum Capital Partners, LLC | 0 |
Reported balance
After 2018-05-24 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2018-05-24 · Conversion · Disposed 1 · Balance 0 F1: Douglas M. VanOort holds voting and dispositive control over Conundrum Capital Partners, LLC. |
Filing footnotes · ownership attribution and instrument terms
F1: Douglas M. VanOort holds voting and dispositive control over Conundrum Capital Partners, LLC.
F2: 36,364 shares at $2.75 per share represent the conversion at maturity of a convertible note initially entered into on August 17, 2017.
F3: 1,199 shares at $4.30 per share represent the payment of interest at 8% on the note.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 01, 2021 Filed Aug 13, 2021 21:12 UTC | NEOGENOMICS INC NEO · Entity 2096 | Tax withholdingCommon Stock | 5,919 | $46.10 | $272,865.90 |
DisclosureSEC source: 0001077183-21-000210 · wf-form4_162888913972963.xml · nonDerivative · entry 2 VAN OORT DOUGLAS M · CIK 0001518733 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,468,797 F1 · shares: Shares surrendered to NeoGenomics Inc. to satisfy the tax obligations in connection with the August 1, 2021 vesting of restricted stock. Read SEC document |
| March 02, 2021 Filed Mar 4, 2021 01:19 UTC | NEOGENOMICS INC NEO · Entity 2096 | GrantCommon Stock | 56,423 | $0.00 | $0.00 |
DisclosureSEC source: 0001077183-21-000086 · wf-form4_161482073084569.xml · nonDerivative · entry 4 VAN OORT DOUGLAS M · CIK 0001518733 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,474,716 Read SEC document |
| March 02, 2021 Filed Mar 4, 2021 01:19 UTC | NEOGENOMICS INC NEO · Entity 2096 | Tax withholdingCommon Stock | 2,158 | $0.00 | $0.00 |
DisclosureSEC source: 0001077183-21-000086 · wf-form4_161482073084569.xml · nonDerivative · entry 3 VAN OORT DOUGLAS M · CIK 0001518733 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,418,293 F2 · shares: Shares surrendered to NeoGenomics Inc. for retirement to satisfy the tax obligations in connection with the March 2, 2021 vesting of restricted stock. Read SEC document |
| March 01, 2021 Filed Mar 4, 2021 01:19 UTC | NEOGENOMICS INC NEO · Entity 2096 | Tax withholdingCommon Stock | 2,339 | $0.00 | $0.00 |
DisclosureSEC source: 0001077183-21-000086 · wf-form4_161482073084569.xml · nonDerivative · entry 2 VAN OORT DOUGLAS M · CIK 0001518733 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,420,451 F1 · shares: Shares surrendered to NeoGenomics Inc. for retirement to satisfy the tax obligations in connection with the March 1, 2021 vesting of restricted stock. Read SEC document |
| November 16, 2020 Filed Nov 17, 2020 01:30 UTC | NEOGENOMICS INC NEO · Entity 2096 | Exercise / conversionStock Option (Right to Buy) · Derivative | 20,000 | $0.00 Strike: $7.52 | $0.00 |
DisclosureSEC source: 0001077183-20-000211 · wf-form4_160557663745672.xml · derivative · entry 10 VAN OORT DOUGLAS M · CIK 0001518733 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 20,000 shares Expires 2022-04-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: On April 28, 2017, Mr. VanOort was granted 500,000 stock options. These options vested ratably over the first three anniversary dates of the grant date. Read SEC document |
| November 16, 2020 Filed Nov 17, 2020 01:30 UTC | NEOGENOMICS INC NEO · Entity 2096 | SaleCommon Stock | 100,000 | $42.34 | $4,234,000.00 |
DisclosureSEC source: 0001077183-20-000211 · wf-form4_160557663745672.xml · nonDerivative · entry 7 VAN OORT DOUGLAS M · CIK 0001518733 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,422,790 Read SEC document |
| November 16, 2020 Filed Nov 17, 2020 01:30 UTC | NEOGENOMICS INC NEO · Entity 2096 | Exercise / conversionCommon Stock | 20,000 | $7.52 | $150,400.00 |
DisclosureSEC source: 0001077183-20-000211 · wf-form4_160557663745672.xml · nonDerivative · entry 6 VAN OORT DOUGLAS M · CIK 0001518733 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,522,790 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 13, 2020 Filed Nov 17, 2020 01:30 UTC | NEOGENOMICS INC NEO · Entity 2096 | Exercise / conversionStock Option (Right to Buy) · Derivative | 358,752 | $0.00 Strike: $7.52 | $0.00 |
DisclosureSEC source: 0001077183-20-000211 · wf-form4_160557663745672.xml · derivative · entry 9 VAN OORT DOUGLAS M · CIK 0001518733 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 358,752 shares Expires 2022-04-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: On April 28, 2017, Mr. VanOort was granted 500,000 stock options. These options vested ratably over the first three anniversary dates of the grant date. Read SEC document |
| November 13, 2020 Filed Nov 17, 2020 01:30 UTC | NEOGENOMICS INC NEO · Entity 2096 | SaleCommon Stock | 118,752 | $41.56 | $4,935,333.12 |
DisclosureSEC source: 0001077183-20-000211 · wf-form4_160557663745672.xml · nonDerivative · entry 5 VAN OORT DOUGLAS M · CIK 0001518733 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,502,790 Read SEC document |
| November 13, 2020 Filed Nov 17, 2020 01:30 UTC | NEOGENOMICS INC NEO · Entity 2096 | Exercise / conversionCommon Stock | 358,752 | $7.52 | $2,697,815.04 |
DisclosureSEC source: 0001077183-20-000211 · wf-form4_160557663745672.xml · nonDerivative · entry 4 VAN OORT DOUGLAS M · CIK 0001518733 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,621,542 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 12, 2020 Filed Nov 17, 2020 01:30 UTC | NEOGENOMICS INC NEO · Entity 2096 | Exercise / conversionStock Option (Right to Buy) · Derivative | 121,248 | $0.00 Strike: $7.52 | $0.00 |
DisclosureSEC source: 0001077183-20-000211 · wf-form4_160557663745672.xml · derivative · entry 8 VAN OORT DOUGLAS M · CIK 0001518733 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 378,752 Underlying: Common Stock · 121,248 shares Expires 2022-04-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: On April 28, 2017, Mr. VanOort was granted 500,000 stock options. These options vested ratably over the first three anniversary dates of the grant date. Read SEC document |
| November 12, 2020 Filed Nov 17, 2020 01:30 UTC | NEOGENOMICS INC NEO · Entity 2096 | SaleCommon Stock | 121,248 | $42.18 | $5,114,240.64 |
DisclosureSEC source: 0001077183-20-000211 · wf-form4_160557663745672.xml · nonDerivative · entry 3 VAN OORT DOUGLAS M · CIK 0001518733 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,262,790 Read SEC document |
| November 12, 2020 Filed Nov 17, 2020 01:30 UTC | NEOGENOMICS INC NEO · Entity 2096 | Exercise / conversionCommon Stock | 121,248 | $7.52 | $911,784.96 |
DisclosureSEC source: 0001077183-20-000211 · wf-form4_160557663745672.xml · nonDerivative · entry 2 VAN OORT DOUGLAS M · CIK 0001518733 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,384,038 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 12, 2020 Filed Aug 13, 2020 20:21 UTC | NEOGENOMICS INC NEO · Entity 2096 | GiftCommon Stock | 10,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001077183-20-000183 · wf-form4_159735006197932.xml · nonDerivative · entry 4 VAN OORT DOUGLAS M · CIK 0001518733 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,262,790 F1 · kind: Mr. VanOort transferred these shares as a bona fide gift pursuant to a transaction exempt from Section 16(b) under Rule 16b-5. Read SEC document |
| August 11, 2020 Filed Aug 13, 2020 20:21 UTC | NEOGENOMICS INC NEO · Entity 2096 | GiftCommon Stock | 5,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001077183-20-000183 · wf-form4_159735006197932.xml · nonDerivative · entry 3 VAN OORT DOUGLAS M · CIK 0001518733 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · Custodial Account for Child Disclosed balance after: 15,000 F2 · kind: Bona fide gift to an account held by Mr. VanOort's child for which Mr. VanOort is the custodian. Read SEC document |
| August 11, 2020 Filed Aug 13, 2020 20:21 UTC | NEOGENOMICS INC NEO · Entity 2096 | GiftCommon Stock | 5,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001077183-20-000183 · wf-form4_159735006197932.xml · nonDerivative · entry 2 VAN OORT DOUGLAS M · CIK 0001518733 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,272,790 F2 · kind: Bona fide gift to an account held by Mr. VanOort's child for which Mr. VanOort is the custodian. Read SEC document |
| August 11, 2020 Filed Aug 13, 2020 20:21 UTC | NEOGENOMICS INC NEO · Entity 2096 | GiftCommon Stock | 10,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001077183-20-000183 · wf-form4_159735006197932.xml · nonDerivative · entry 1 VAN OORT DOUGLAS M · CIK 0001518733 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,277,790 F1 · kind: Mr. VanOort transferred these shares as a bona fide gift pursuant to a transaction exempt from Section 16(b) under Rule 16b-5. Read SEC document |
| August 01, 2020 Filed Aug 4, 2020 21:47 UTC | NEOGENOMICS INC NEO · Entity 2096 | Tax withholdingCommon Stock | 5,953 | $0.00 | $0.00 |
DisclosureSEC source: 0001077183-20-000173 · wf-form4_159657754692322.xml · nonDerivative · entry 2 VAN OORT DOUGLAS M · CIK 0001518733 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,287,790 F1 · shares: Shares surrendered to NeoGenomics Inc. to satisfy the tax obligations in connection with the August 1, 2020 vesting of restricted stock. Read SEC document |
| May 25, 2020 Filed May 27, 2020 21:24 UTC | NEOGENOMICS INC NEO · Entity 2096 | Tax withholdingCommon Stock | 22,330 | $0.00 | $0.00 |
DisclosureSEC source: 0001077183-20-000118 · wf-form4_159061466388858.xml · nonDerivative · entry 2 VAN OORT DOUGLAS M · CIK 0001518733 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,293,743 F1 · shares: Shares surrendered to NeoGenomics Inc. to satisfy the tax obligations in connection with the May 25, 2020 vesting of restricted stock. Read SEC document |
| March 02, 2020 Filed Mar 4, 2020 01:03 UTC | NEOGENOMICS INC NEO · Entity 2096 | GrantCommon Stock · Derivative | 225,084 | $28.33 Strike: $28.33 | $6,376,629.72 |
DisclosureSEC source: 0001077183-20-000032 · wf-form4_158328381578221.xml · derivative · entry 7 VAN OORT DOUGLAS M · CIK 0001518733 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 225,084 Underlying: Common Stock · 225,084 shares Expires 2027-03-02 F5 · derivative.exercise_date: On March 2, 2020, Mr. VanOort was granted 225,084 stock options. These options vest ratably over the first four anniversary dates of the grant date. Read SEC document |
| March 02, 2020 Filed Mar 4, 2020 01:03 UTC | NEOGENOMICS INC NEO · Entity 2096 | GrantCommon Stock | 34,945 | $0.00 | $0.00 |
DisclosureSEC source: 0001077183-20-000032 · wf-form4_158328381578221.xml · nonDerivative · entry 3 VAN OORT DOUGLAS M · CIK 0001518733 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,316,073 Read SEC document |
| March 01, 2020 Filed Mar 4, 2020 01:03 UTC | NEOGENOMICS INC NEO · Entity 2096 | Tax withholdingCommon Stock | 2,353 | $0.00 | $0.00 |
DisclosureSEC source: 0001077183-20-000032 · wf-form4_158328381578221.xml · nonDerivative · entry 2 VAN OORT DOUGLAS M · CIK 0001518733 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,281,128 F1 · shares: Shares withheld by NeoGenomics Inc. to satisfy the tax obligations in connection with the March 1, 2020 vesting of restricted stock. Read SEC document |
| November 19, 2019 Filed Nov 21, 2019 22:32 UTC | NEOGENOMICS INC NEO · Entity 2096 | SaleCommon Stock | 187,500 | $24.08 | $4,515,000.00 |
DisclosureSEC source: 0001077183-19-000217 · wf-form4_157437553229846.xml · nonDerivative · entry 3 VAN OORT DOUGLAS M · CIK 0001518733 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · Conundrum Capital Partners Disclosed balance after: 0 F1 · ownership.nature: Conundrum Capital Partners, LLC is a limited liability partnership 50% owned by Mr. VanOort. Mr. VanOort is a managing partner of Conundrum Capital Partners, LLC Read SEC document |
| November 08, 2019 Filed Nov 13, 2019 22:43 UTC | NEOGENOMICS INC NEO · Entity 2096 | Exercise / conversionStock Option (Right to Buy · Derivative | 472,527 | $0.00 Strike: $7.15 | $0.00 |
DisclosureSEC source: 0001077183-19-000208 · wf-form4_157368500878449.xml · derivative · entry 6 VAN OORT DOUGLAS M · CIK 0001518733 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 472,527 shares Expires 2021-04-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: On April 20, 2016, Mr. VanOort was granted 472,527 stock options. These options vest ratably over the first three anniversary dates of the grant date. Read SEC document |
| November 08, 2019 Filed Nov 13, 2019 22:43 UTC | NEOGENOMICS INC NEO · Entity 2096 | Tax withholdingCommon Stock | 205,635 | $0.00 | $0.00 |
DisclosureSEC source: 0001077183-19-000208 · wf-form4_157368500878449.xml · nonDerivative · entry 5 VAN OORT DOUGLAS M · CIK 0001518733 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,277,391 F4 · shares: Shares withheld by NeoGenomics, Inc. for the cost of exercise and to satisfy the tax obligations in connection with the November 8, 2019 exercise of stock options. Read SEC document |
| November 08, 2019 Filed Nov 13, 2019 22:43 UTC | NEOGENOMICS INC NEO · Entity 2096 | Exercise / conversionCommon Stock | 472,527 | $7.15 | $3,378,568.05 |
DisclosureSEC source: 0001077183-19-000208 · wf-form4_157368500878449.xml · nonDerivative · entry 4 VAN OORT DOUGLAS M · CIK 0001518733 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,483,026 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 29, 2019 Filed Sep 3, 2019 21:25 UTC | NEOGENOMICS INC NEO · Entity 2096 | GiftCommon Stock | 10,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001077183-19-000164 · wf-form4_156754589955907.xml · nonDerivative · entry 5 VAN OORT DOUGLAS M · CIK 0001518733 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,016,589 F2 · kind: Mr. VanOort transferred these shares as a bona fide gift pursuant to a transaction exempt from Section 16(b) under Rule 16b-5. Read SEC document |
| August 28, 2019 Filed Sep 3, 2019 21:25 UTC | NEOGENOMICS INC NEO · Entity 2096 | GiftCommon Stock | 10,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001077183-19-000164 · wf-form4_156754589955907.xml · nonDerivative · entry 4 VAN OORT DOUGLAS M · CIK 0001518733 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · Custodial Account for Child Disclosed balance after: 10,000 F3 · kind: Bona fide gift to an account held by Mr. VanOort's child for which Mr. VanOort is the custodian. Read SEC document |
| August 28, 2019 Filed Sep 3, 2019 21:25 UTC | NEOGENOMICS INC NEO · Entity 2096 | GiftCommon Stock | 10,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001077183-19-000164 · wf-form4_156754589955907.xml · nonDerivative · entry 3 VAN OORT DOUGLAS M · CIK 0001518733 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,026,589 F3 · kind: Bona fide gift to an account held by Mr. VanOort's child for which Mr. VanOort is the custodian. Read SEC document |
| August 28, 2019 Filed Sep 3, 2019 21:25 UTC | NEOGENOMICS INC NEO · Entity 2096 | GiftCommon Stock | 30,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001077183-19-000164 · wf-form4_156754589955907.xml · nonDerivative · entry 2 VAN OORT DOUGLAS M · CIK 0001518733 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,036,589 F2 · kind: Mr. VanOort transferred these shares as a bona fide gift pursuant to a transaction exempt from Section 16(b) under Rule 16b-5. Read SEC document |
| August 01, 2019 Filed Nov 13, 2019 22:43 UTC | NEOGENOMICS INC NEO · Entity 2096 | Tax withholdingCommon Stock | 6,090 | $0.00 | $0.00 |
DisclosureSEC source: 0001077183-19-000208 · wf-form4_157368500878449.xml · nonDerivative · entry 3 VAN OORT DOUGLAS M · CIK 0001518733 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,010,499 F2 · shares: Shares withheld by NeoGenomics Inc. to satisfy the tax obligations in connection with the August 1, 2019 vesting of restricted stock F3 · balance_after: Total reflects transactions which occurred on August 28 and 29, 2019 and reported on Form 4 on September 3, 2019. Read SEC document |
| May 25, 2019 Filed May 30, 2019 00:50 UTC | NEOGENOMICS INC NEO · Entity 2096 | Tax withholdingCommon Stock | 25,846 | $0.00 | $0.00 |
DisclosureSEC source: 0001077183-19-000097 · wf-form4_155917738612994.xml · nonDerivative · entry 2 VAN OORT DOUGLAS M · CIK 0001518733 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,066,589 F2 · shares: Shares withheld by NeoGenomics Inc. to satisfy the tax obligations in connection with the May 25, 2019 vesting of restricted stock. Read SEC document |
| March 01, 2019 Filed Mar 5, 2019 22:10 UTC | NEOGENOMICS INC NEO · Entity 2096 | GrantStock Option (Right to Buy) · Derivative | 231,567 | $19.60 Strike: $19.60 | $4,538,713.20 |
DisclosureSEC source: 0001077183-19-000037 · wf-form4_155182381624439.xml · derivative · entry 3 VAN OORT DOUGLAS M · CIK 0001518733 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 231,567 Underlying: Common Stock · 231,567 shares Expires 2024-03-01 F2 · derivative.exercise_date: On March 1, 2019, Mr. VanOort was granted an option to purchase 231,567 shares of NeoGenomics, Inc. common stock. The options vest ratably over the first four anniversary dates of the grant date. Read SEC document |
| March 01, 2019 Filed Mar 5, 2019 22:10 UTC | NEOGENOMICS INC NEO · Entity 2096 | GrantCommon Stock | 37,883 | $0.00 | $0.00 |
DisclosureSEC source: 0001077183-19-000037 · wf-form4_155182381624439.xml · nonDerivative · entry 2 VAN OORT DOUGLAS M · CIK 0001518733 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,092,435 Read SEC document |
| August 03, 2018 Filed Aug 3, 2018 20:21 UTC Amendment | NEOGENOMICS INC NEO · Entity 2096 | Tax withholdingCommon Stock | 21,904 | $0.00 | $0.00 |
DisclosureSEC source: 0001077183-18-000071 · wf-form4a_153332765483832.xml · nonDerivative · entry 1 VAN OORT DOUGLAS M · CIK 0001518733 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,008,123 F1 · shares: Shares withheld by NeoGenomics Inc. to satisfy the tax obligations in connection with the May 25, 2018 vesting of restricted stock. F2 · balance_after: This Amended Form 4 reflects the corrected presentation of the securities beneficially owned following the withholding of shares to satisfy tax obligations (noted in Footnote 1). This correction is the result of a restricted stock award granted on May 25, 2017 which was inadvertently classified in Table II and was moved to Table I on a Form 4/A filed on August 3, 2018 which amended the Form 4 originally filed on May 30, 2017. Read SEC document |
| August 03, 2018 Filed Aug 3, 2018 20:14 UTC Amendment | NEOGENOMICS INC NEO · Entity 2096 | GrantCommon Stock | 197,042 | $0.00 | $0.00 |
DisclosureSEC source: 0001077183-18-000069 · wf-form4a_153332725921133.xml · nonDerivative · entry 1 VAN OORT DOUGLAS M · CIK 0001518733 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,030,027 F1 · shares: This Amended Form 4 reflects the corrected presentation of a restricted stock award granted on 5/25/2017; this award was inadvertently classified in Table II and is being moved to Table I. This error also appears in the subsequent Form 4 filed on February 28, 2018. Read SEC document |
| August 01, 2018 Filed Aug 3, 2018 20:27 UTC | NEOGENOMICS INC NEO · Entity 2096 | GrantCommon Stock | 46,429 | $0.00 | $0.00 |
DisclosureSEC source: 0001077183-18-000073 · wf-form4_153332803778209.xml · nonDerivative · entry 1 VAN OORT DOUGLAS M · CIK 0001518733 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,054,552 F1 · shares: On August 1, 2018, Mr. VanOort was granted 46,429 shares of restricted stock. These shares vest ratably over the first three anniversary dates of the grant date. Read SEC document |
| May 25, 2018 Filed May 29, 2018 23:00 UTC | NEOGENOMICS INC NEO · Entity 2096 | Exercise / conversionRestricted Stock · Derivative | 65,680 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001077183-18-000032 · wf-form4_152763484053208.xml · derivative · entry 4 VAN OORT DOUGLAS M · CIK 0001518733 · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 131,362 Underlying: Common Stock · 65,680 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · security: Each share of restricted stock represents the contingent right to receive one share of common stock upon vesting of the unit. F4 · derivative.exercise_date: Restricted stock will vest as follows; 65,680 shares vested on May 25, 2018 and 65,681 shares will vest on May 25, 2019 and 2020. F5 · derivative.expiration_date: The shares of restricted stock will terminate upon the earliest of death, termination of employment or the last vesting date. Read SEC document |
| May 25, 2018 Filed May 29, 2018 23:00 UTC | NEOGENOMICS INC NEO · Entity 2096 | Tax withholdingCommon Stock | 21,904 | $11.57 | $253,429.28 |
DisclosureSEC source: 0001077183-18-000032 · wf-form4_152763484053208.xml · nonDerivative · entry 2 VAN OORT DOUGLAS M · CIK 0001518733 · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,876,761 F1 · shares: Shares withheld by NeoGenomics Inc. to satisfy the tax obligations in connection with the May 25, 2018 vesting of restricted stock. Read SEC document |
| May 25, 2018 Filed May 29, 2018 23:00 UTC | NEOGENOMICS INC NEO · Entity 2096 | Exercise / conversionCommon Stock | 65,680 | $0.00 | $0.00 |
DisclosureSEC source: 0001077183-18-000032 · wf-form4_152763484053208.xml · nonDerivative · entry 1 VAN OORT DOUGLAS M · CIK 0001518733 · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,898,665 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 24, 2018 Filed May 25, 2018 17:04 UTC | RENOVARE ENVIRONMENTAL, INC. BHTG · Entity 128802 | ConversionConvertible Promissory Note · Derivative | 1 | $100,000.00 Strike: $2.75 | $100,000.00 |
DisclosureSEC source: 0001144204-18-031027 · tv495043_4.xml · derivative · entry 3 VAN OORT DOUGLAS M · CIK 0001518733 · Director CONUNDRUM CAPITAL PARTNERS, LLC · CIK 0001658011 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · Held by Conundrum Capital Partners, LLC Disclosed balance after: 0 Underlying: Common Stock · 36,364 shares Expires 2018-05-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · ownership.nature: Douglas M. VanOort holds voting and dispositive control over Conundrum Capital Partners, LLC. Read SEC document |
| May 24, 2018 Filed May 25, 2018 17:04 UTC | RENOVARE ENVIRONMENTAL, INC. BHTG · Entity 128802 | ConversionCommon Stock, par value $0.0001 | 1,199 | $4.30 | $5,155.70 |
DisclosureSEC source: 0001144204-18-031027 · tv495043_4.xml · nonDerivative · entry 2 VAN OORT DOUGLAS M · CIK 0001518733 · Director CONUNDRUM CAPITAL PARTNERS, LLC · CIK 0001658011 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · Held by Conundrum Capital Partners, LLC Disclosed balance after: 914,427 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · shares: 1,199 shares at $4.30 per share represent the payment of interest at 8% on the note. F1 · ownership.nature: Douglas M. VanOort holds voting and dispositive control over Conundrum Capital Partners, LLC. Read SEC document |
| May 24, 2018 Filed May 25, 2018 17:04 UTC | RENOVARE ENVIRONMENTAL, INC. BHTG · Entity 128802 | ConversionCommon Stock, par value $0.0001 | 36,364 | $2.75 | $100,001.00 |
DisclosureSEC source: 0001144204-18-031027 · tv495043_4.xml · nonDerivative · entry 1 VAN OORT DOUGLAS M · CIK 0001518733 · Director CONUNDRUM CAPITAL PARTNERS, LLC · CIK 0001658011 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · Held by Conundrum Capital Partners, LLC Disclosed balance after: 913,228 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · shares: 36,364 shares at $2.75 per share represent the conversion at maturity of a convertible note initially entered into on August 17, 2017. F1 · ownership.nature: Douglas M. VanOort holds voting and dispositive control over Conundrum Capital Partners, LLC. Read SEC document |
| April 11, 2018 Filed Apr 13, 2018 20:40 UTC | RENOVARE ENVIRONMENTAL, INC. BHTG · Entity 128802 | ConversionConvertible Promissory Note · Derivative | 1 | $100,000.00 Strike: $2.75 | $100,000.00 |
DisclosureSEC source: 0001144204-18-020524 · tv491013_4.xml · derivative · entry 3 VAN OORT DOUGLAS M · CIK 0001518733 · Director CONUNDRUM CAPITAL PARTNERS, LLC · CIK 0001658011 · Director Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · Held by Conundrum Capital Partners, LLC Disclosed balance after: 0 Underlying: Common Stock · 36,364 shares Expires 2018-04-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · ownership.nature: 3,204 shares at $4.994 per share represent the payment of interest at 8% on the Note. Read SEC document |
| April 11, 2018 Filed Apr 13, 2018 20:40 UTC | RENOVARE ENVIRONMENTAL, INC. BHTG · Entity 128802 | ConversionCommon Stock, par value $0.0001 | 3,204 | $4.99 | $16,000.78 |
DisclosureSEC source: 0001144204-18-020524 · tv491013_4.xml · nonDerivative · entry 2 VAN OORT DOUGLAS M · CIK 0001518733 · Director CONUNDRUM CAPITAL PARTNERS, LLC · CIK 0001658011 · Director Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · Held by Conundrum Capital Partners, LLC Disclosed balance after: 876,864 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · shares: 3,204 shares at $4.994 per share represent the payment of interest at 8% on the Note. F2 · ownership.nature: Mr. VanOort holds voting and dispositive power over Conundrum Capital Partners, LLC. Read SEC document |
| April 11, 2018 Filed Apr 13, 2018 20:40 UTC | RENOVARE ENVIRONMENTAL, INC. BHTG · Entity 128802 | ConversionCommon Stock, par value $0.0001 | 36,364 | $2.75 | $100,001.00 |
DisclosureSEC source: 0001144204-18-020524 · tv491013_4.xml · nonDerivative · entry 1 VAN OORT DOUGLAS M · CIK 0001518733 · Director CONUNDRUM CAPITAL PARTNERS, LLC · CIK 0001658011 · Director Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · Held by Conundrum Capital Partners, LLC Disclosed balance after: 873,660 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: 36,364 shares at $2.75 per share represent the conversion at maturity of a convertible note initially entered into on February 10, 2016 (the "Note"). F2 · ownership.nature: Mr. VanOort holds voting and dispositive power over Conundrum Capital Partners, LLC. Read SEC document |
| February 26, 2018 Filed Feb 28, 2018 23:40 UTC | NEOGENOMICS INC NEO · Entity 2096 | GrantStock Option (Right to Buy) · Derivative | 636,000 | $8.03 Strike: $8.03 | $5,107,080.00 |
DisclosureSEC source: 0001209191-18-014675 · doc4.xml · derivative · entry 6 VAN OORT DOUGLAS M · CIK 0001518733 · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 636,000 Underlying: Common Stock · 636,000 shares Expires 2023-02-26 F8 · derivative.exercise_date: On February 26, 2018, Mr. VanOort was granted 636,000 stock options. These options vest ratably over the first three anniversary dates of the grant date. Read SEC document |
| February 26, 2018 Filed Mar 28, 2018 20:58 UTC Amendment | NEOGENOMICS INC NEO · Entity 2096 | GrantStock Option (Right to Buy) · Derivative | 500,000 | $8.03 Strike: $8.03 | $4,015,000.00 |
DisclosureSEC source: 0001628280-18-003730 · wf-form4a_152227067929061.xml · derivative · entry 1 VAN OORT DOUGLAS M · CIK 0001518733 · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 500,000 Underlying: Common Stock · 500,000 shares Expires 2023-02-26 F1 · shares: The number of shares of common stock covered by this stock option grant exceeded a limitation applicable to equity awards under the Amended and Restated Equity Incentive Plan and 136,000 excess options were rescinded. This Amended Form 4 reflects the corrected number of stock options granted. Except as otherwise stated above, the vesting and other terms and conditions of the stock option will remain unchanged. F2 · derivative.exercise_date: On February 26, 2018, Mr. VanOort was granted stock options; these stock options vest ratably over the first three anniversary dates of the grant date. Read SEC document |
| August 17, 2017 Filed Aug 22, 2017 21:45 UTC | RENOVARE ENVIRONMENTAL, INC. BHTG · Entity 128802 | OtherWarrants · Derivative | 36,364 | $0.00 Strike: $3.30 | $0.00 |
DisclosureSEC source: 0001144204-17-044640 · v473844_4.xml · derivative · entry 2 VAN OORT DOUGLAS M · CIK 0001518733 · Director CONUNDRUM CAPITAL PARTNERS, LLC · CIK 0001658011 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · Held by Conundrum Capital Partners, LLC Disclosed balance after: 36,364 Underlying: Common Stock · 36,364 shares Expires 2022-08-17 F4 · derivative.exercise_price: Based on 120% of the conversion price of $2.75 per share. The warrants are exercisable into an indeterminable number of shares. F5 · derivative.underlying_shares: Represents the number of shares of Common Stock into which the warrants are exercisable based on the exercise price of $3.30 per share. Read SEC document |
| August 17, 2017 Filed Aug 22, 2017 21:45 UTC | RENOVARE ENVIRONMENTAL, INC. BHTG · Entity 128802 | OtherConvertible Promissory Note · Derivative | 1 | $100,000.00 Strike: $2.75 | $100,000.00 |
DisclosureSEC source: 0001144204-17-044640 · v473844_4.xml · derivative · entry 1 VAN OORT DOUGLAS M · CIK 0001518733 · Director CONUNDRUM CAPITAL PARTNERS, LLC · CIK 0001658011 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · Held by Conundrum Capital Partners, LLC Disclosed balance after: 1 Underlying: Common Stock · 36,364 shares Expires 2019-07-06 F1 · derivative.exercise_price: Represents the highest possible conversion price of the note. F2 · derivative.underlying_shares: Represents the number of shares of common stock, par value $$0.0001 per share ("Common Stock") into which the note is convertible based on the conversion price of $2.75 per share. The note is convertible into an indeterminable number of shares. F3 · balance_after: Does not include 837,296 shares held by Conundrum Capital Partners, LLC ("Conundrum") over which Mr. VanOort holds voting and dispositive power. The address of Conundrum is 317 Eatons Landing Drive, Annapolis, MD 21401. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.